Adalvo continues to strengthen its peptide & biosimilar portfolio with the addition of Pancreatin Delayed-Release Capsules, a blockbuster treatment addressing a critical need in Exocrine Pancreatic Insufficiency (EPI).
Pancreatin is the #1 prescribed therapy for EPI, a condition affecting over 1 million patients worldwide. Clinical studies confirm its effectiveness in improving fat, protein, and carbohydrate absorption in patients with EPI caused by chronic pancreatitis, cystic fibrosis, and pancreatectomy.
The reference brand, Creon (AbbVie), leads the Pancreatic Enzyme Replacement Therapy (PERT) segment, with more than 8 out of 10 gastroenterologists choosing it over other PERT options.
With the global pancreatin market valued at $4.5 billion in 2024 (IQVIA), Adalvo positions itself among the key players in this segment.
The dossier is currently under approval in Europe, with a launch planned across key European markets in Q1 2026.
Through a launch-on-approval strategy, Adalvo aims to expand market access and provide a high-quality alternative, further strengthening its gastroenterology portfolio.
Get In Touch Today!